دورية أكاديمية
[A 5'-DFUR + CPA + THP therapy that was effective for paclitaxel-refractory pulmonary metastasis of breast cancer--a case report].
| العنوان: | [A 5'-DFUR + CPA + THP therapy that was effective for paclitaxel-refractory pulmonary metastasis of breast cancer--a case report]. |
|---|---|
| المؤلفون: | Kitahara S; Second Dept. of Surgery, School of Medicine, Toho University., Ogata H, Katagiri T, Nonaka K, Shiba T |
| المصدر: | Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2002 Jan; Vol. 29 (1), pp. 111-4. |
| نوع المنشور: | Case Reports; English Abstract; Journal Article |
| اللغة: | Japanese |
| بيانات الدورية: | Publisher: Gan To Kagaku Ryohosha Country of Publication: Japan NLM ID: 7810034 Publication Model: Print Cited Medium: Print ISSN: 0385-0684 (Print) Linking ISSN: 03850684 NLM ISO Abbreviation: Gan To Kagaku Ryoho Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Tokyo : Gan To Kagaku Ryohosha Original Publication: Tōkyō, Gan to Kagaku Ryōhōsha [1974?]- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*drug therapy , Breast Neoplasms/*pathology , Lung Neoplasms/*drug therapy , Lung Neoplasms/*secondary, Adult ; Antineoplastic Agents, Phytogenic/pharmacology ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Female ; Floxuridine/administration & dosage ; Humans ; Paclitaxel/pharmacology |
| مستخلص: | What should be the standard treatment for taxane-refractory metastatic breast cancer remains controversial. In this paper, a case in which the 5'-DFUR + CPA + THP therapy was effective for paclitaxel-refractory metastatic breast cancer is reported. A 41-year-old female received pectoral muscle preserved mastectomy under diagnosis of the left breast cancer in May 1996. In June, 1999, a coin lesion of 2.2 cm diameter was found in the left middle lung field with chest X-ray. Paclitaxel 210 mg/m2 (once for three weeks, 8 cycles in total) resulted in marked improvement. The regimen of paclitaxel 70 mg/m2 (medication consecutive once-weekly for three weeks, and withdrawal for next week; 1 cycle) was carried out continuously with the patient ambulatory. Because resistance to the treatment appeared at the time the total dose reached 2,700 mg, 5'-DFUR + CPA + THP therapy (THP 30 mg/m2 (i.v.) x day 1, CPA 77 mg/m2 (p.o.) x 14 days, 5'-DFUR 460 mg/m2 (p.o.) x 14 days; 3 weeks with 1 cycle) was carried out, and definite improvement in the lung findings were observed. 5'-DFUR + CPA + THP therapy may be of use as a second-line therapy in paclitaxel-refractory recurrent breast cancer. |
| المشرفين على المادة: | 0 (Antineoplastic Agents, Phytogenic) 039LU44I5M (Floxuridine) 80168379AG (Doxorubicin) 8N3DW7272P (Cyclophosphamide) D58G680W0G (pirarubicin) P88XT4IS4D (Paclitaxel) V1JK16Y2JP (doxifluridine) |
| تواريخ الأحداث: | Date Created: 20020131 Date Completed: 20020205 Latest Revision: 20151123 |
| رمز التحديث: | 20221213 |
| PMID: | 11816465 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0385-0684 |
|---|